BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 27,000 Shares

September 29, 2026 by InsiderTrades.com

Key Points

CEO Ugur Sahin sold 27,000 BioNTech shares at an average price of $98.69, generating approximately $2.66 million. The sale was made under a pre-arranged Rule 10b5-1 plan, and he retained 314,209 shares afterward.
Sahin has made a series of recent sales, including 34,000 shares on September 28 and additional transactions throughout September, signaling substantial scheduled share disposals rather than necessarily a change in outlook.
BioNTech recently reported a quarterly loss and a 59.5% year-over-year revenue decline. Analysts nevertheless maintain a consensus “Moderate Buy” rating with a $126 price target, while site closures and mRNA patent litigation add near-term risks.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 27,000 shares of BioNTech stock in a transaction on Friday, September 25th. The shares were sold at an average price of $98.69, for a total value of $2,664,630.00. Following the transaction, the chief executive officer owned 314,209 shares in the company, valued at $31,009,286.21. This trade represents a 7.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

4 Reasons Pfizer Could Be a Value Play You Can't Miss

Ugur Sahin also recently made the following trade(s):

On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.47, for a total value of $3,347,980.00.
On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The stock was sold at an average price of $98.99, for a total value of $3,860,610.00.
On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total value of $2,982,000.00.
On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The stock was sold at an average price of $100.72, for a total value of $4,633,120.00.
On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total value of $3,227,730.00.
On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total value of $2,886,600.00.
On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.60, for a total transaction of $3,352,400.00.
On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total transaction of $1,441,350.00.
On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $96.49, for a total transaction of $3,280,660.00.
On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total transaction of $4,077,450.00.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $99.08 on Tuesday. The company has a market capitalization of $25.06 billion, a P/E ratio of -12.65 and a beta of 1.29. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The firm's 50 day simple moving average is $98.31 and its two-hundred day simple moving average is $94.84. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80.

Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.40) by ($0.13). The firm had revenue of $122.31 million during the quarter, compared to analysts' expectations of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The business's revenue for the quarter was down 59.5% on a year-over-year basis. During the same period last year, the company earned ($1.60) earnings per share. Research analysts expect that BioNTech SE Sponsored ADR will post -6.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. UBS Group reiterated a "buy" rating on shares of BioNTech in a research note on Wednesday, September 16th. Weiss Ratings restated a "sell (d-)" rating on shares of BioNTech in a research report on Monday, July 6th. Morgan Stanley dropped their price objective on BioNTech from $126.00 to $119.00 and set an "overweight" rating for the company in a research note on Wednesday, July 8th. Canaccord Genuity Group cut their target price on BioNTech from $142.00 to $136.00 and set a "buy" rating for the company in a research report on Monday, August 31st. Finally, Wall Street Zen downgraded BioNTech from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $126.00.

Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?

View Our Latest Analysis on BNTX

Key Headlines Impacting BioNTech

Here are the key news stories impacting BioNTech this week:

Neutral Sentiment: CEO Ugur Sahin sold a combined 61,000 shares for approximately $6.0 million in transactions dated September 25 and 28. Because both sales were conducted under a pre-arranged Rule 10b5-1 trading plan, they may reflect scheduled diversification rather than a change in management’s outlook. Sahin still owns 280,209 shares. SEC insider trading filing
Negative Sentiment: BioNTech said it will close manufacturing sites in Germany and Singapore after failing to find buyers. The closures underscore excess capacity and the company’s ongoing retrenchment from pandemic-era COVID-19 vaccine manufacturing, potentially adding restructuring costs and highlighting weaker near-term demand. They could eventually improve efficiency by reducing fixed expenses. Reuters: BioNTech to shutter sites
Negative Sentiment: A court reportedly dealt Pfizer, BioNTech and Moderna a setback in efforts to dismiss lawsuits involving mRNA patents. The development may increase legal costs and raise potential financial or licensing exposure for BioNTech, although the ultimate liability remains uncertain. Pfizer, BioNTech and Moderna patent litigation

Institutional Investors Weigh In On BioNTech

A number of hedge funds have recently made changes to their positions in BNTX. AlphaCentric Advisors LLC raised its holdings in shares of BioNTech by 5.7% during the 1st quarter. AlphaCentric Advisors LLC now owns 5,616 shares of the company's stock worth $499,000 after acquiring an additional 305 shares in the last quarter. USS Investment Management Ltd grew its holdings in shares of BioNTech by 1.2% in the first quarter. USS Investment Management Ltd now owns 32,577 shares of the company's stock valued at $2,854,000 after purchasing an additional 382 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in BioNTech in the second quarter worth $39,000. Marks Group Wealth Management Inc increased its position in BioNTech by 16.0% in the first quarter. Marks Group Wealth Management Inc now owns 3,454 shares of the company's stock worth $307,000 after purchasing an additional 476 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in BioNTech by 1,012.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company's stock valued at $53,000 after purchasing an additional 506 shares in the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

About BioNTech

(Get Free Report)

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.